• Return to Headlines

Relatively Good Performance Detected in Shares of Nektar Therapeutics in the Pharmaceuticals Industry (NKTR, NVO, ENDP, ELN, XNPT)

Written on Fri, 10/28/2011 - 5:45am
By David Diaz

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the potential to outperform.
Nektar Therapeutics (NASDAQ:NKTR) ranks first with a gain of 9.72%; Novo Nordisk (NYSE:NVO) ranks second with a gain of 8.16%; and Endo Pharmaceuticals (NASDAQ:ENDP) ranks third with a gain of 7.57%.
Elan (NYSE:ELN) follows with a gain of 6.72% and XenoPort (NASDAQ:XNPT) rounds out the top five with a gain of 6.25%.
SmarTrend currently has shares of Nektar Therapeutics in a Downtrend and issued the Downtrend alert on May 24, 2011 at $9.10. The stock has fallen 39.2% since the Downtrend alert was issued.

Keywords: nektar therapeutics relative performance

Ticker(s): NKTR NVO ENDP ELN XNPT

Contact David Diaz



Smartrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.mysmartrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at http://www.mysmartrend.com/morning-call-newsletter-signup.